{"filings":[{"id":94859,"accession_number":"0001193125-26-151259","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Solid Biosciences reclassifies director Ilan Ganot from Class III to Class I to balance board composition","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ilan Ganot resigned from Class III effective 4:00 p.m. ET on April 10, 2026.","Board reduced Class III to three directors and increased Class I to three, appointing Ganot to Class I with term expiring at 2028 Annual Meeting.","Ganot's compensation arrangements unchanged; no compensation due for resignation or appointment.","Company will seek advisory ratification of Ganot's appointment as Class I Director at 2026 Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107541,"accession_number":"0001193125-26-102489","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Solid Biosciences reports positive interim SGT-003 data; microdystrophin expression 60% at Day 90, 91% at Day 360","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["40 participants dosed; SGT-003 well tolerated with steroid-only immunomodulation regimen.","Day 90 biopsy (n=20): mean microdystrophin expression 60% (western blot), 63% positive fibers; 60% beta-sarcoglycan restoration.","Day 360 biopsy (n=3): microdystrophin expression 91% (western blot), 69% positive fibers; 69% beta-sarcoglycan restoration.","Biomarker improvements: CK -38%, ALT -43%, AST -30%, LDH -46%, eMHC -44% at Day 90.","FDA aligned on Phase 3 design; screening underway; first participant dosing expected Q1 2026; accelerated approval discussions planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107540,"accession_number":"0001193125-26-096709","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["1.01","2.02","3.02","8.01","9.01"],"status":"ready","headline":"Solid Biosciences raises ~$240M in private placement; prelim cash ~$188M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$240M from 14.97M shares at $5.61 and 27.81M pre-funded warrants at $5.609.","Preliminary cash, equivalents and securities ~$187.9M as of Dec 31, 2025 (unaudited).","Net proceeds extend runway into H1 2028; funds pipeline development, BD, and G&A.","Investors include Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, and others.","Private placement expected to close March 9, 2026; Leerink and Citi lead placement agents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123889,"accession_number":"0001193125-25-262795","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Solid Biosciences Q3 cash $236.1M; INSPIRE DUCHENNE shows 58% microdystrophin expression, strong biomarker correlations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and available-for-sale securities: $236.1M as of Sep 30, 2025; runway into H1 2027.","Interim INSPIRE DUCHENNE data (N=10 at Day 90): mean microdystrophin expression 58% by western blot and mass spectrometry, positive fibers 51%.","Statistical correlations (Pearson r=0.95) between microdystrophin and beta-sarcoglycan/nNOS restoration; r=-0.78 for CK reduction at Day 180.","Safety: SGT-003 generally well tolerated with steroid-only prophylaxis; one Grade 3 myositis SAE resolved; no DILI; asymptomatic platelet declines ameliorated.","Regulatory: FDA meeting planned H1 2026 to discuss accelerated approval; Phase 3 IMPACT DUCHENNE initiated ex-US; SGT-212 and SGT-501 trials activated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158257,"accession_number":"0000950170-25-086215","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"SLDB stockholders approve doubling authorized shares to 240M and adding 9M shares to equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 120M to 240M via Certificate of Amendment filed June 12, 2025.","Equity plan amended to add 9M shares and modify evergreen provision to 6% annual increase from 2026.","Class I directors Alexander Cumbo and Sukumar Nagendran re-elected with 95% and 92% of votes cast, respectively.","PricewaterhouseCoopers ratified as auditor for FY2025 with 68.9M votes for, 18.8K against.","Say-on-pay advisory vote approved with 57.1M for vs. 5.1M against; 6.6M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158256,"accession_number":"0000950170-25-072792","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Solid Biosciences ups ATM offering capacity to $85M; $10.5M already sold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement on May 15, 2025 to increase ATM offering from $75M to $85M.","Prior prospectus had $75M capacity; $10.5M in gross proceeds sold as of filing date.","Offering conducted under existing S-3 shelf registration statement via Jefferies LLC.","Legal opinion of Wilmer Cutler Pickering Hale and Dorr LLP attached as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176637,"accession_number":"0001193125-25-028691","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Solid Biosciences prices $200M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced public offering of 35.7M shares at $4.03/share and pre-funded warrants for 13.9M shares at $4.029 each; gross proceeds ~$200M.","Net proceeds estimated at $187.5M after underwriting discounts and expenses; offering expected to close Feb 19, 2025.","Investors include Adage Capital Partners, Bain Capital Life Sciences, Invus, Perceptive Advisors, RA Capital Management, others.","Jefferies, Leerink Partners, William Blair act as joint book-runners; H.C. Wainwright as lead manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176636,"accession_number":"0001193125-25-028146","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Solid Biosciences prices $200M underwritten offering; extends cash runway into first half 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced $200M underwritten offering expected to close Feb 19, 2025; net proceeds to fund R&D for SGT-003 and other candidates.","Company estimates cash runway into first half of 2027, but notes offering alone may not fully fund development of all candidates.","Remaining proceeds for general corporate purposes; existing cash and securities combined for operating plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176635,"accession_number":"0001193125-25-028123","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Solid Biosciences reports 110% avg microdystrophin expression from SGT-003 Phase 1/2 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First three participants showed average 110% microdystrophin expression by western blot and 78% dystrophin-positive fibers at Day 90.","Mean reductions in muscle injury biomarkers: CK -57%, AST -45%, ALT -54%, LDH -60% at Day 90.","Two participants at Day 180 showed mean LVEF increase of 8% from baseline; no serious adverse events or TMA observed.","Preliminary cash, cash equivalents and available-for-sale securities of ~$148.9M as of Dec 31, 2024.","Company plans mid-2025 FDA meeting to discuss accelerated approval for SGT-003; enrollment ongoing with 7th dosed Feb 17."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227974,"accession_number":"0001193125-24-159143","cik":1707502,"company_name":"Solid Biosciences Inc.","ticker":"SLDB","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Solid Biosciences directors Koppel and Shah resign; shareholders approve doubling authorized shares to 120M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Adam Koppel and Rajeev Shah resigned from the Board effective June 11, 2024; no disagreement cited.","Shareholders approved increase of authorized common stock from 60M to 120M shares.","Equity incentive plan amended to add 2M shares; total available for issuance increased accordingly.","Four Class III directors elected: Martin Freed, Ilan Ganot, Georgia Keresty, Ian Smith.","Advisory vote on executive compensation held every year; PricewaterhouseCoopers ratified as auditor for FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":692100741.0754987,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}